A retrospective analysis: comparison of nephrotoxicity caused by concurrent weekly cisplatin in patients of head & neck cancer and cervical cancer
DOI:
https://doi.org/10.18203/2320-6012.ijrms20250668Keywords:
Carcinoma cervix, Concurrent chemoradiation, Head and neck cancer, NephrotoxicityAbstract
Background: Cisplatin is the most common chemotherapeutic drug which is used concurrently with radiation therapy due to its radio sensitizing effect. Cisplatin is known to cause substantial amount of nephrotoxicity and adequate hydration is absolutely essential while administering cisplatin. Once weekly regimen is widely used both in the treatment of head & neck cancers as well as cervical cancer. The main aim of this study is to compare the incidence and severity of nephrotoxicity in patients of head and neck and cervical cancer treated with concurrent chemoradiation
Methods: From January 2023 to December 2023, data of 50 patients each of head and neck cancer and cervical cancer patients treated at our institute was evaluated. Cisplatin was used weekly at the dose of 40 mg/m2 with adequate hydration and necessary pre medications in all the patients. CBC, RFT and Serum Electrolytes were done prior to each cycle. RIFLE criteria were used to classify renal impairment
Results: 50 patients each of head and neck and cervical cancer were selected. Total 5 cycles of concurrent cisplatin were planned in both the arms according to the institutional protocol. During the course of treatment, Renal impairment was seen in 32 out of 50 patients (64%) in head and neck cancer arm whereas in ca cervix arm it was seen in only 14/50 patients (28%)
Conclusions: Renal impairment is more pronounced in head and neck cancer patients as compared to cervical cancer patients thus more aggressive hydration measures are required in patients of head and neck cancer.
Metrics
References
Tharavichitkul E, Lorvidhaya V, Kamnerdsupaphon P, Sukthomya V, Chakrabandhu S, Klunklin P, et al. Combined chemoradiation of cisplatin versus carboplatin in cervical carcinoma: a single institution experience from Thailand. BMC Cancer. 2016;16:501. DOI: https://doi.org/10.1186/s12885-016-2558-9
Porosnicu M, Faig J, Haughton M, Taylor RC. Retrospective analysis of cisplatin nephrotoxicity in patients with head and neck cancer receiving outpatient treatment with concurrent high-dose cisplatin and radiotherapy. American J of Clin Oncol. 2018;41:432–40. DOI: https://doi.org/10.1097/COC.0000000000000301
Yamamoto Y, Watanabe K, Matsushita H, Tsukiyama I, Matsuura K, Wakatsuki A. Multivariate analysis of risk factors for cisplatin-induced nephrotoxicity in gynecological cancer. J of Obst and Gynaecol Res. 2017;43:1880–6. DOI: https://doi.org/10.1111/jog.13457
Bagri PK, Kapoor A, Kalwar A, Singhal MK, Singh D, Narayan S. Comparative analysis of cisplatin-induced nephrotoxicity in head and neck cancer and carcinoma cervix during concurrent chemoradiotherapy. South Asian J Cancer. 2014;3(4):217-20. DOI: https://doi.org/10.4103/2278-330X.142979
Motwani SS, McMahon GM, Humphreys BD, Partridge AH, Waikar SS, Curhan GC. Development and validation of a risk prediction model for acute kidney injury after the first course of cisplatin. J Clin Oncol. 2018;36(7):682-8. DOI: https://doi.org/10.1200/JCO.2017.75.7161
Pignon JP, le Maître A, Maillard E, Bourhis J, MACH‑NC Collaborative Group. Meta‑analysis of chemotherapy in head and neck cancer (MACH‑NC): An update on 93 randomised trials and 17,3416 patients. Radiother Oncol. 2009;92:4‑14. DOI: https://doi.org/10.1016/j.radonc.2009.04.014
Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration (CCCMAC). Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: individual patient data meta-analysis. Cochrane Data Sys Rev. 2010;6(1):8285.
Richmond RC. Toxic variability and radiation sensitization by dichlorodiammineplatinum (II) complexes in Salmonella typhimurium cells. Radiat Res. 1984;99:596‑60. DOI: https://doi.org/10.2307/3576334
Santoso JT, Lucci JA 3rd, Coleman RL. Saline, mannitol and furosemide hydration in acute cisplatin nephrotoxicity:a randomized trial. Cancer Chemother Pharmacol. 2003;52:13-8. DOI: https://doi.org/10.1007/s00280-003-0620-1
NCI Clinical Announcement: Concurrent Chemoradiation for Cervical Cancer. Washington: United States Department of Public Health. 1999:78.
Hartmann JT, Kollmannsberger C, Kanz L. Platinum organ toxicity and possible prevention in patients with testicular cancer. Int J Cancer. 1999;83:866–9. DOI: https://doi.org/10.1002/(SICI)1097-0215(19991210)83:6<866::AID-IJC34>3.0.CO;2-9
Rose PG. Chemoradiotherapy for cervical cancer. Eur J Cancer. 2002;38:270‑8. DOI: https://doi.org/10.1016/S0959-8049(01)00352-5
Einstein MH, Novetsky AP, Garg M, Hailpern SM, Huang GS, Glueck A, et al. Survival and toxicity differences between 5‑day and weekly cisplatin in patients with locally advanced cervical cancer. Cancer. 2007;109:48‑53. DOI: https://doi.org/10.1002/cncr.22369
Bachaud JM, Cohen‑Jonathan E, Alzieu C, David JM, Serrano E, Daly‑Schveitzer N. Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced head and neck carcinoma: Final report of a randomized trial. Int J Radiat Oncol Biol Phys. 1996;36:999‑1004. DOI: https://doi.org/10.1016/S0360-3016(96)00430-0
Santos NA, Carvalho Rodrigues MA, Martins NM. Cisplatin-induced nephrotoxicity and targets of nephroprotection: an update. Arch Toxicol. 2012;86:1233–50. DOI: https://doi.org/10.1007/s00204-012-0821-7
Shord SS, Thompson DM, Krempl GA. Effect of concurrent medications on cisplatin-induced nephrotoxicity in patients with head and neck cancer. Anticancer Drugs. 2006;17:207–15. DOI: https://doi.org/10.1097/00001813-200602000-00013
Downloads
Published
How to Cite
Issue
Section
